The return of investment for preventive healthcare programmes

The return of investment

for preventive healthcare

programmes

A calculation framework for GSK¡¯s

Partnership for Prevention (P4P)

Martin Stepanek, Marco Hafner, Jirka Taylor,

Sarah Grand-Clement and Chris van Stolk

E U R OPE

For more information on this publication, visit t/RR1787

Published by the RAND Corporation, Santa Monica, Calif., and Cambridge, UK

? Copyright 2017 RAND Corporation

R? is a registered trademark.

RAND Europe is a not-for-profit organisation whose mission is to help improve policy and decision making through

research and analysis. RAND¡¯s publications do not necessarily reflect the opinions of its research clients and sponsors.

Limited Print and Electronic Distribution Rights

This document and trademark(s) contained herein are protected by law. This representation of RAND

intellectual property is provided for noncommercial use only. Unauthorized posting of this publication

online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is

unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of

its research documents for commercial use. For information on reprint and linking permissions, please visit

pubs/permissions.

Support RAND

Make a tax-deductible charitable contribution at

giving/contribute



randeurope

Preface

This report aims to summarise the existing evidence on the effectiveness of workplace related preventive

health programmes, outlining the challenges involved in calculating the return on investment (ROI) of

such interventions.

This report is funded by GlaxoSmithKline (GSK).

ii

Abstract

This report describes a modelling framework for calculating the return on investment (ROI) for GSK¡¯s

Partnership for Prevention preventive healthcare progamme. Subsequently, general challenges in

calculating an ROI for preventive health programmes are discussed and evidence on the effectiveness of

specific interventions is included in Partnership for Prevention is outlined. The report includes a case

study to calculate the Partnership for Prevention¡¯s ROI in South Africa.

iii

Table of Contents

Preface ...................................................................................................................................................... ii

Abstract .................................................................................................................................................... iii

Table of Contents .................................................................................................................................... iv

Figures ..................................................................................................................................................... vi

Tables ..................................................................................................................................................... vii

Summary ............................................................................................................................................... viii

Acknowledgements ................................................................................................................................... x

Abbreviations ........................................................................................................................................... xi

1. Introduction ....................................................................................................................................... 1

1.1. Background .................................................................................................................................. 1

1.2. Why should a business invest in health promotion and disease prevention? .................................. 2

1.3. GSK¡¯s Partnership for Prevention ................................................................................................. 3

1.4. Objectives of the study ................................................................................................................. 4

1.5. Research approach ........................................................................................................................ 4

1.6. Structure of this report ................................................................................................................. 5

2. Drivers of a successful workplace health prevention programme.......................................................... 6

2.1. What determines good practice and successful workplace health promotion programmes? ............ 6

2.2. How does GSK¡¯s Partnership for Prevention compares against good practices in health

prevention programmes? .............................................................................................................. 7

3. The challenges in measuring returns on investments for preventive healthcare programmes ................ 9

3.1. Challenges in measuring ROI of preventive healthcare programmes ............................................. 9

4. Evidence on the effectiveness of workplace health prevention programmes and interventions ........... 11

4.1. Evidence on the impact of workplace health prevention programmes ......................................... 11

4.2. Applicability of the evidence to GSK¡¯s Partnership for Prevention .............................................. 13

5. A framework to calculate the ROI of preventive healthcare programmes ........................................... 19

5.6. The ROI of Partnership for Prevention in South Africa .............................................................. 37

Discussion ............................................................................................................................................... 39

iv

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download